Achieve Life Sciences (ACHV) Competitors $4.18 +0.02 (+0.48%) (As of 02:01 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACHV vs. SGMO, EBS, CDXS, RIGL, XOMA, VNDA, VSTM, LXRX, RGLS, and AGENShould you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Sangamo Therapeutics (SGMO), Emergent BioSolutions (EBS), Codexis (CDXS), Rigel Pharmaceuticals (RIGL), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), Regulus Therapeutics (RGLS), and Agenus (AGEN). These companies are all part of the "biotechnology" industry. Achieve Life Sciences vs. Sangamo Therapeutics Emergent BioSolutions Codexis Rigel Pharmaceuticals XOMA Vanda Pharmaceuticals Verastem Lexicon Pharmaceuticals Regulus Therapeutics Agenus Sangamo Therapeutics (NASDAQ:SGMO) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership. Do analysts rate SGMO or ACHV? Sangamo Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 148.23%. Achieve Life Sciences has a consensus price target of $14.80, indicating a potential upside of 255.77%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than Sangamo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Which has more risk and volatility, SGMO or ACHV? Sangamo Therapeutics has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Which has stronger valuation & earnings, SGMO or ACHV? Achieve Life Sciences has lower revenue, but higher earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSangamo Therapeutics$52.29M11.25-$257.83M-$0.75-3.76Achieve Life SciencesN/AN/A-$29.82M-$1.13-3.68 Does the MarketBeat Community prefer SGMO or ACHV? Sangamo Therapeutics received 116 more outperform votes than Achieve Life Sciences when rated by MarketBeat users. However, 70.46% of users gave Achieve Life Sciences an outperform vote while only 62.67% of users gave Sangamo Therapeutics an outperform vote. CompanyUnderperformOutperformSangamo TherapeuticsOutperform Votes45062.67% Underperform Votes26837.33% Achieve Life SciencesOutperform Votes33470.46% Underperform Votes14029.54% Is SGMO or ACHV more profitable? Achieve Life Sciences has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -257.87%. Achieve Life Sciences' return on equity of -108.30% beat Sangamo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics-257.87% -264.16% -107.24% Achieve Life Sciences N/A -108.30%-65.20% Do insiders & institutionals have more ownership in SGMO or ACHV? 56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 2.8% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media favor SGMO or ACHV? In the previous week, Sangamo Therapeutics had 12 more articles in the media than Achieve Life Sciences. MarketBeat recorded 12 mentions for Sangamo Therapeutics and 0 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.89 beat Sangamo Therapeutics' score of 0.36 indicating that Achieve Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Sangamo Therapeutics Neutral Achieve Life Sciences Positive SummaryAchieve Life Sciences beats Sangamo Therapeutics on 12 of the 18 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Achieve Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHV vs. The Competition Export to ExcelMetricAchieve Life SciencesDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$143.06M$2.71B$5.18B$9.31BDividend YieldN/A0.74%4.78%4.06%P/E Ratio-3.686.29130.2217.53Price / SalesN/A72.271,246.14139.51Price / CashN/A15.1641.2337.95Price / Book-59.433.344.884.92Net Income-$29.82M$31.95M$119.65M$225.78M7 Day Performance-1.89%-3.95%16.62%-1.56%1 Month PerformanceN/A12.11%16.34%6.68%1 Year Performance25.68%-19.68%35.38%22.48% Achieve Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHVAchieve Life Sciences1.6965 of 5 stars$4.18+0.5%$14.80+254.1%+30.8%$143.75MN/A-3.7020SGMOSangamo Therapeutics1.9033 of 5 stars$2.49+21.5%$7.00+181.1%+579.4%$519.54M$176.23M-3.11480Analyst UpgradeHigh Trading VolumeEBSEmergent BioSolutions4.1689 of 5 stars$8.84+4.2%$14.00+58.4%+268.9%$478.99M$1.09B-2.071,600CDXSCodexis4.2441 of 5 stars$5.65+2.2%$8.33+47.5%+95.5%$459.79M$64.45M-6.36250Positive NewsRIGLRigel Pharmaceuticals4.2964 of 5 stars$19.17+1.4%$36.20+88.8%+43.0%$337.58M$116.88M135.08147XOMAXOMA4.4241 of 5 stars$27.40+0.9%$81.50+197.4%+72.3%$322.77M$4.76M-7.8010VNDAVanda Pharmaceuticals4.3318 of 5 stars$4.66+1.1%$15.50+232.6%+21.9%$271.72M$190.86M-16.54203VSTMVerastem3.6237 of 5 stars$4.71+5.1%$12.50+165.4%-39.6%$209.63M$10M-1.4050News CoveragePositive NewsGap UpLXRXLexicon Pharmaceuticals2.0881 of 5 stars$0.83+2.0%$6.00+625.8%-42.2%$203.56M$5.23M-1.08285RGLSRegulus Therapeutics2.9405 of 5 stars$1.67+5.4%$10.80+548.6%+18.2%$109.06MN/A-1.4830Positive NewsAGENAgenus3.9358 of 5 stars$2.88-5.6%$10.00+247.2%-78.6%$67.56M$160.43M-0.27389Positive News Related Companies and Tools Related Companies SGMO Alternatives EBS Alternatives CDXS Alternatives RIGL Alternatives XOMA Alternatives VNDA Alternatives VSTM Alternatives LXRX Alternatives RGLS Alternatives AGEN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACHV) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achieve Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
